using standard solid phase synthesis techniques employing Boc chemistry. Amino acids and resins for synthesis were purchased from Bachem California and the amino acids were analyzed by TLC and polarimetry prior to use. The peptid es were cleaved from the solid support using anhydrous hydrogen fluoride and conventional techniques. Each peptide was 6304p Protocol 118 04/06/2016 purified by HPLC using a Waters Delta -prep system with a gradient of acetonitrile (containing 0.1% trifluoroacetic acid) in water (also containing 0.1% trifluoroacetic acid). The peptides were lyophilized to dryness before being passed over an anion exchange column to exchange the trifluoroacetate for acetate. GMP procedures were followed for the manufacture of these sequences. The pept ides were characterized by mass spectrometry to confirm their identity, by HPLC for purity using two different elution buffers, and by amino acid analysis for identity and peptide content. The water content of each peptide was determined by the Karl Fischer procedure and the data obtained used to verify the mass balance of the peptides. C. Peptide formulation and stability Prior to formulation, the solubility of each peptide in 10 mM sodium acetate buffer (pH 4.0) was determined. Three peptides were mad e up in a 10 mM sodium acetate buffer (pH 4.0). The stability of each individual peptide in the acetate buffer, as well as the peptide mixtures, is monitored by HPLC and mass spectrometry. The dissolved peptides are stored at - 20˚C prior to use. Microbi al and sterility testing are conducted to ensure safety.